1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsRapid Response Partnership Vehicle (RRPV) is sponsored by BARDA. A flexible partnership mechanism to support the rapid development of medical countermeasures for public health emergencies.
Get alerted about grants like this
Save a search for “BARDA” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Contract Award Data Processing Delay Show Details) May 4, 2026 At this time, all Contract Data reports are correct as of May 2nd, 2026. We will remove this warning once the data refresh is completed. Thank You.
This processing delay impacts:Contract awards searchDatabank awards reportsSubcontract award reportingService Contract Inventory reportingBio-preferred Reporting Subcontracting Plan Reporting Contract Retrieval Issue Show Details) Apr 17, 2026 SAM. gov users of the Subcontracting Plan Reporting module, may currently experience difficulties when trying to retrieve Prime Contracts and Subcontracts within their Workspace.
We are aware of this issue and are actively working on a resolution. We appreciate your patience while we address this issue. This alert will be removed once the issue is resolved.
# RRPV Solicitation Summary: Rapid Antigen Production for Immunoassay Diagnostics (RAPID) HEALTH AND HUMAN SERVICES, DEPARTMENT OF BARDA - ASPR / DAAPPO / BARDA DCMA * **Contract Opportunity Type:**Special Notice (Original) * **Original Published Date:**Apr 15, 2026 03:00 pm EDT * **Original Response Date:**May 13, 2026 01:00 pm EDT * **Inactive Policy:**15 days after response date * **Original Inactive Date:**May 28, 2026 * **Original Set Aside:**No Set aside used * **Product Service Code:** AN42 - HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH * 541714 - Research and Development in Biotechnology (except Nanobiotechnology) * **Place of Performance:** This solicitation summary is to notify all potential offerors of a Request for Project Proposals (RPP) issued through the Rapid Response Partnership Vehicle (RRPV) Consortium on behalf of the Biomedical Advanced Research and Development Authority (BARDA) entitiled "Rapid Antigen Production for Immunoassay Diagnostics (RAPID)".
Through the Rapid Antibody Production for Immunoassay Diagnostics (RAPID) RPP, BARDA seeks to support advanced research and development of rapid antibody and other protein-based molecular recognition reagent generation platforms to enable timely production of immunoassay-ready reagents for diagnostic use.
The objective is to establish flexible, end-to-end systems capable of generating high-performance binders against known and emerging biological threats, with the goal of significantly compressing development timelines from pathogen sequence to assay-ready reagents—ideally within weeks.
A Proposer’s Conference and Teaming Connect for the Rapid Antibody Production for Immunoassay Diagnostics (RAPID) RPP will take place virtually on Monday, April 27, 2026 from 11am-12pm EST. The full RPP, how to register for the Conference, and information on joining the consortium can be accessed through the RRPV website - www. rrpv.
org. ### Contracting Office Address * O’NEILL HOUSE OFFICE BUILDING ### Primary Point of Contact ### Secondary Point of Contact * **Apr 15, 2026 03:00 pm EDT**Special Notice (Original) What changes or improvements would you suggest? * Freedom of Information Act * Freedom of Information Act This is a U.S. General Services Administration Federal Government computer system that is **"FOR OFFICIAL USE ONLY."
** This system is subject to monitoring. Individuals found performing unauthorized activities are subject to disciplinary action including criminal prosecution. This system contains Controlled Unclassified Information (CUI).
All individuals viewing, reproducing or disposing of this information are required to protect it in accordance with 32 CFR Part 2002 and GSA Order CIO 2103. 2 CUI Policy.
Based on current listing details, eligibility includes: Nonprofits, Universities, State/local governments, Small businesses, For-profit organizations Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.